Remibrutinib
CAS 1787294-07-8Small Molecule
Overview
Remibrutinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4483575).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Remibrutinib expires 19 Jan 2043 and exclusivity 30 Sept 2030. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide
- Canonical SMILES
- CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C
- InChIKey
- CUABMPOJOBCXJI-UHFFFAOYSA-N
Verified Supplier Partner
Do you supply Remibrutinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.